ENDRA Life Sciences Files 8-K

TL;DR

ENDRA Life Sciences filed an 8-K on 10/23/25 covering financial statements and other events.

AI Summary

ENDRA Life Sciences Inc. filed an 8-K on October 23, 2025, reporting on various events. The filing includes information related to financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company, formerly known as Endra Inc., is incorporated in Delaware and headquartered in Ann Arbor, Michigan.

Why It Matters

This 8-K filing provides updates on ENDRA Life Sciences Inc.'s corporate activities, including financial reporting and other material events, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on standard corporate events and financial information, not indicating any immediate significant risks.

Key Players & Entities

• ENDRA Life Sciences Inc. (company) — Registrant
• Endra Inc. (company) — Former company name
• October 23, 2025 (date) — Date of report
• Ann Arbor, MI (location) — Principal executive offices
• Delaware (location) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share NDRA The Nasdaq Stock Mar
• $3,000,000 — estimated total value of approximately $3,000,000 as of October 21, 2025 to launch its DA

Filing Documents

• endra_8k.htm (8-K) — 31KB
• endra_ex991.htm (EX-99.1) — 15KB
• endra_ex992.htm (EX-99.2) — 10KB
• endra_ex993.htm (EX-99.3) — 54KB
• 0001654954-25-012084.txt ( ) — 251KB
• endra-20251023.xsd (EX-101.SCH) — 5KB
• endra-20251023_lab.xml (EX-101.LAB) — 14KB
• endra-20251023_cal.xml (EX-101.CAL) — 1KB
• endra-20251023_pre.xml (EX-101.PRE) — 9KB
• endra-20251023_def.xml (EX-101.DEF) — 2KB
• endra_8k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 23, 2025, ENDRA Life Sciences Inc. (the "Company") issued a press release announcing the closing of the private placement offering (the "Offering") to implement a digital asset treasury (the "DAT") as previously disclosed on the Current Report on Form 8-K filed with the Securities and Exchange Commission (the "Commission") on October 15, 2025. A copy of the press release is included as Exhibit 99.1 hereto and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On October 23, 2025, the Company announced that it had purchased 78,863.1 HYPE tokens with an estimated total value of approximately $3,000,000 as of October 21, 2025 to launch its DAT. In connection with the DAT, the Company is filing an updated description of its business to supplement that contained in the Company's prior public filings. The description of the Company's DAT is filed herewith as Exhibit 99.2 and is incorporated herein by reference. In connection with the DAT, the Company is filing supplemental risk factors pertaining to its digital asset treasury business to update disclosures contained in the Company's prior public filings, including those discussed under the heading "Item 1A. Risk Factors" in (i) the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 31, 2025, (ii) the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 15, 2025, and (iii) the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Commission on August 14, 2025. The supplemental risk factors are filed herewith as Exhibit 99.3 and are incorporated herein by reference.

Forward-Looking Statements

Forward-Looking Statements All statements in this Current Report on Form 8-K that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as "approximate," "anticipate," "attempt," "believe," "could," "estimate," "expect," "forecast," "future," "goal," "hope," "intend," "may," "plan," "possible," "potential," "project," "seek," "should," "will," "would," or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: expectations regarding our DAT strategy and ability to execute such strategy successfully; our limited commercial and DAT experience, limited cash and history of losses; our ability to obtain adequate financing to fund our business operations or DAT strategy in the future; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; regulatory developments related to crypto assets and crypto asset markets; a determination that we are an investment company under the Investment Company Act of 1940; any changes in the accounting treatment of cryptocurrency holdings; the risk that the price of the Company's common stock may be highly correlated to the price of the digital assets that it holds; our ability to regain compliance with Nasdaq listing standards; our dependence on our senior management team; and the other risks and uncertainties described in the Risk Factors and Management's Discuss

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Number Description 99.1 Press Release dated October 23, 2025, furnished herewith 99.2 Description of Digital Asset Strategy 99.3 Supplemental Risk Factors 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENDRA Life Sciences Inc. October 23, 2025 By: /s/ Richard Jacroux Name: Richard Jacroux Title: Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR